Vaderis is enrolling participants in an HHT clinical study. HHT can involve frequent nosebleeds, fatigue, anemia, and uncertainty; Vaderis says it is advancing research that may improve life for people with HHT.
BMP9 and BMP10 maintain blood vessel stability by signaling through a receptor complex comprising ALK1 (ACVRL1), Endoglin (ENG), and BMPRII. ENG or ACVRL1 mutations disrupt this pathway.
Participant video Argentina Spanish Belgium Dutch French German Bulgaria Bulgarian Canada English French France French Germany German Hungary Hungarian Italy Italian Lithuania Lithuanian Netherlands Dutch Spain Spanish United Kingdom English United States English Spanish
The HHT Clinical Study invites adults with HHT to express interest in participating; additional information and next steps may be shared. Final eligibility is determined during formal screening.
Vaderis was founded on the belief that science guided by courage and empathy can change lives for people with rare vascular diseases. In 2019, it focused on hereditary hemorrhagic telangiectasia (HHT).
HHT, also known as Osler Weber Rendu syndrome, is a rare autosomal dominant disorder involving abnormal blood vessel formation. The page describes it as a severe disease with no approved therapies and the second most common inherited bleeding disorder.
